All News

The FDA ordered 4 companies to stop selling 44 of their flavored e-liquid and hookah tobacco products that lack the required approval for sale; CMS has yet to implement a 2014 law preventing unnecessary, expensive screening tests (magnetic resonance imaging, computed tomagraphy scans and other tests) that could harm patients and waste resources; Amarin, which is seeking FDA approval for an expansion of Vascepa labeling to include data that showed a 25% reduction in the risk of heart attacks and strokes, said the FDA has scheduled an advisory committee meeting for November 14.

The fiscal year 2020 (FY2020) Inpatient Prospective Payment Systems (IPPS) proposed rule notably includes approximately 1500 complications or comorbidities (CC)/major complications or comorbidities (MCC) designation changes and 324 changes to International Classification of Diseases, Tenth Revision, Clinical Modification codes, along with several other updates. The designation changes are an effort to respond to the notion that the CC/MCC assignment are no longer appropriate as conditions and factors have shifted.

Novartis hid manipulated data about its $2 million gene therapy Zolgensma from the FDA; US District Judge Kristine Baker granted a preliminary injunction preventing Arkansas from enforcing 3 abortion restrictions; a federal judge in Ohio expressed support for a plan by attorneys representing cities and counties suing US opioid manufacturers and distributors that would bring every US community into their settlement talks despite objections from most states.

Federal regulators have caught on to a growing trend of clinical trials asking participants to pay to enroll; Canada's main pharmaceutical lobby group is asking the government to respond to US drug importation plans before Canada experiences drug shortages; with more HIV incidence than any other region, the South is turning to telemedicine to treat people living with the infection.

Authorized generics, released by brand-pharmaceutical companies as a way to deal with competition, can be as profitable as, if not more profitable than, brand-name drugs; an increasing reliance on fundraising appeals for healthcare needs can widen existing disparities and distort markets, particularly for prescription drugs; the Trump administration is considering releasing a healthcare plan in the fall.

Using bronchodilators early on in patients with chronic obstructive pulmonary disease (COPD) is increasingly understood to be an important therapeutic intervention to improve quality of life, inhibit disease progression, and allow for greater physical activity. One recent paper sought to compare 2 treatment options with respect to their impact on pulmonary function, health-related quality of life, and physical activity: twice-daily inhalation therapy with aclidinium and once-daily inhalation therapy with tiotropium.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text